knowledge -WSS

knowledge

author：hotspot 2025-09-14 14:43:10 - browse：739

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

Wikipedia

WSS

eGenesis tests gene

STAT Summit: The economic case for universal basic health care

Roivant's CEO is a star, but biotech's black hole persists

Humana cuts profit projections as Medicare Advantage costs soar

ADCs take center stage as promising cancer treatments

Merck, Daiichi strike cancer drug pact worth up to $22 billion

entertainment

knowledge

hotspot

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: Ending the crisis of Black deaths in the U.S.

After affirmative action ruling, medical educators look to 'holistic review'

Think you might have Covid

How one medical school became remarkably diverse

STAT Summit: Meghan O’Rourke on making chronic illness visible

Malaria cases in Florida and Texas: Here’s what you need to know

Dewpoint Therapeutics lays off staff after losing partnerships

State Dept. review finds Biden bears some blame for Afghanistan failures

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Readout: Friday, Oct. 20 biotech updates

FDA clears Verve to begin U.S. study of gene

EU regulator recommends expanding Mounjaro approval to obesity

Dewpoint Therapeutics lays off staff after losing partnerships

Independent physicians launch a new lobbying group

leisure time

Wikipedia

knowledge

focus